ACADIA Pharmaceuticals Net Income 2006-2021 | ACAD

ACADIA Pharmaceuticals net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
ACADIA Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-282
2019 $-235
2018 $-245
2017 $-289
2016 $-271
2015 $-164
2014 $-92
2013 $-38
2012 $-21
2011 $-23
2010 $15
2009 $-45
2008 $-64
2007 $-56
2006 $-45
2005 $-34
ACADIA Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-09-30 $-14
2021-06-30 $-44
2021-03-31 $-66
2020-12-31 $-67
2020-09-30 $-85
2020-06-30 $-42
2020-03-31 $-88
2019-12-31 $-53
2019-09-30 $-42
2019-06-30 $-55
2019-03-31 $-85
2018-12-31 $-65
2018-09-30 $-62
2018-06-30 $-63
2018-03-31 $-54
2017-12-31 $-69
2017-09-30 $-65
2017-06-30 $-67
2017-03-31 $-88
2016-12-31 $-79
2016-09-30 $-72
2016-06-30 $-71
2016-03-31 $-50
2015-12-31 $-46
2015-09-30 $-39
2015-06-30 $-39
2015-03-31 $-40
2014-12-31 $-28
2014-09-30 $-25
2014-06-30 $-21
2014-03-31 $-18
2013-12-31 $-12
2013-09-30 $-11
2013-06-30 $-9
2013-03-31 $-6
2012-12-31 $-7
2012-09-30 $-2
2012-06-30 $-5
2012-03-31 $-6
2011-12-31 $-5
2011-09-30 $-5
2011-06-30 $-7
2011-03-31 $-6
2010-12-31 $29
2010-09-30 $-4
2010-06-30 $-4
2010-03-31 $-5
2009-12-31 $-9
2009-09-30 $-9
2009-06-30 $-13
2009-03-31 $-15
2008-12-31 $-14
2008-09-30 $-16
2008-06-30 $-18
2008-03-31 $-16
2007-12-31 $-17
2007-09-30 $-16
2007-06-30 $-11
2007-03-31 $-13
2006-12-31 $-12
2006-09-30 $-11
2006-06-30 $-12
2006-03-31 $-9
2005-12-31 $-10
2005-09-30 $-12
2005-06-30 $-6
2005-03-31 $-6
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.705B $0.442B
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69